eligibility_summary
Eligible: histologically confirmed aggressive B‑NHL with available tumor tissue, primary refractory or relapse ≤12 months after frontline, exactly 1 prior line with anti‑CD20 plus anthracycline, measurable disease (nodal >1.5 cm or extranodal >1.0 cm by CT/MRI), intent for ASCT, ECOG 0–1, adequate hematologic/organ function. Exclude: CNS lymphoma/disease, significant comorbidities, inadequate washout or active infection, drug/excipient allergy, other cancers unless cured ≥3y (some in situ/skin allowed).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized, open-label trial in relapsed/refractory aggressive B‑cell NHL. Interventions: 1) Odronextamab (REGN1979), a full‑length anti‑CD20 × anti‑CD3 bispecific monoclonal antibody immunotherapy that binds CD20 on malignant B cells and CD3 on T cells to redirect/activate cytotoxic T‑cell killing. 2) Standard salvage chemoimmunotherapy (ICE, DHAP, or GDP ± rituximab) with ASCT for responders. SOC mechanisms/types: ifosfamide (alkylating agent, DNA crosslinks), carboplatin/cisplatin (platinum DNA crosslinkers), etoposide (topoisomerase II inhibitor), cytarabine and gemcitabine (antimetabolite nucleoside analogs inhibiting DNA synthesis), rituximab (anti‑CD20 mAb causing B‑cell depletion), dexamethasone (glucocorticoid). Targets/pathways: CD20+ B cells, CD3/T‑cell receptor activation, and DNA replication/repair–mediated apoptosis in rapidly dividing lymphoma cells.